1,721,009 research outputs found
Causes and Mechanisms of Arterial Stiffness
No full textThe aorta is a blood vessel that provides a low-resistance path for blood flow directed from the heart to peripheral organs and tissues. However, the aorta has another central hemodynamic function, whereby the elastic nature of the aortic wall provides a significant biomechanical buffering capacity complementing the pulsatile cardiac blood flow, and this is often referred to as Windkessel function. Stiffening of the arterial wall leads to fundamental alterations in central hemodynamics, with widespread detrimental implications for organ function. In this Recent Highlights article, we describe recent contributions in ATVB that have highlighted the novel mechanisms and consequences of arterial stiffness and the clinical conditions in which arterial stiffness occurs, with a focus on advancements in the field
Transcription factor Runx2 is induced in vascular aging and may promote age-related arterial stiffness
No full textTranscription factor Runx2 is induced in vascular aging and may promote age-related arterial stiffness
No full textMicroRNA miR-29b is a mediator of aortic stiffness and hypertension in a murine model of diabetes mellitus type 2
No full textAbstract 678: microRNA 146a Reduces Activity of Matrix-Metalloproteinases in the Context of Arterial Stiffness
No full textUnresolved Issues in RNA Therapeutics in Vascular Diseases With a Focus on Aneurysm Disease
No full textNew technologies have greatly shaped the scientific and medical landscape within the last years. The unprecedented expansion of data and information on RNA biology has led to the discovery of new RNA classes with unique functions and unexpected modifications. Today, the biggest challenge is to transfer the large number of findings in basic RNA biology into corresponding clinical RNA-based therapeutics. Lately, this research begins to yield positive outcomes. RNA drugs advance to the final phases of clinical trials or even receive FDA approval. Furthermore, the introduction of the RNA-guided gene-editing technology CRISPR and advances in the delivery of messenger RNAs have triggered a major progression in the field of RNA-therapeutics. Especially short interfering RNAs and antisense oligonucleotides are promising examples for novel categories of therapeutics. However, several issues need to be addressed including intracellular delivery, toxicity, and immune responses before utilizing RNAs in a clinical setting. In this review, we provide an overview on opportunities and challenges for clinical translation of RNA-based therapeutics, with an emphasis on advances in novel delivery technologies and abdominal aortic aneurysm disease where non-coding RNAs have been shown to play a crucial regulatory role
MicroRNA miR-29b is a mediator of aortic stiffness and hypertension in a murine model of diabetes mellitus type 2
No full textNON-CODING RNAS COMPREHENSIVELY COUNTERACT ADVERSE ARTERIAL REMODELING AND STIFFENING IN TYPE 2 DIABETES
No full textNON-CODING RNAS COMPREHENSIVELY COUNTERACT ADVERSE ARTERIAL REMODELING AND STIFFENING IN TYPE 2 DIABETES
No full text- …
